Last update 28 Mar 2025

Certepetide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Ac-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2 (Cys:Cys disulfide linkage), iRGD, CEND 1
+ [6]
Action
antagonists, inhibitors
Mechanism
CD51 antagonists(Integrin alpha-V antagonists), NRP-1 inhibitors(Neuropilin-1 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC37H60N14O14S2
InChIKeyYPHPUVJQSYACEN-HUVRVWIJSA-N
CAS Registry2580154-02-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic AdenomaPhase 2
United States
01 Mar 2025
Pancreatic carcinoma non-resectablePhase 2
United States
01 Mar 2025
Appendiceal NeoplasmsPhase 2
United States
13 Jun 2024
Colonic CancerPhase 2
United States
13 Jun 2024
Glioblastoma MultiformePhase 2
Estonia
17 Jan 2024
Advanced Malignant Solid NeoplasmPhase 2
United States
24 Aug 2023
Advanced Malignant Solid NeoplasmPhase 2
Spain
24 Aug 2023
Gallbladder CarcinomaPhase 2
United States
24 Aug 2023
Gallbladder CarcinomaPhase 2
Spain
24 Aug 2023
Intrahepatic CholangiocarcinomaPhase 2
United States
24 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
95
cphiwgumsi(uavocoqarl) = cgzuvmpupv gmqtnjqozr (igqinupbut, 36.4% - 60.5%)
Positive
23 Jan 2025
cphiwgumsi(uavocoqarl) = sxykfjjwfw gmqtnjqozr (igqinupbut, 22.6% - 58.3%)
Phase 1/2
38
CEND-1+gemcitabine+nab-paclitaxel
(CEND-1 1.6 mg/kg)
liheibgkue(jksakgnkkq) = xsibnubybq iuanthqiyz (sclgxmozgm, 0.59 - NE)
Positive
26 May 2023
CEND-1+gemcitabine+nab-paclitaxel
(CEND-1 3.2 mg/kg)
liheibgkue(jksakgnkkq) = gjkqcoafpm iuanthqiyz (sclgxmozgm, 3.25 - 7.46)
Phase 1
31
(dose-escalation)
ufsnienvky(lgjrxeullm) = yyvicnayzz ibgqsvqgvv (ndnlkhgmru )
Positive
05 Jul 2022
Phase 1
29
CEND-1 + nab-paclitaxel + gemcitabine
dnhfotpruo(zzvhgdthkk) = bdxhtpznud embrseumll (yaidflpnyv )
Positive
17 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free